HOME >> MEDICINE >> NEWS
New analysis supports starting with VFEND for life-threatening fungal infections

NEW YORK, October 25, 2005 A new analysis of treatment procedures for the potentially deadly fungal infection invasive aspergillosis suggests that making the right treatment decision as soon as possible after diagnosis may be crucial to survival.

The retrospective analysis, published in the Nov. 15 issue of Clinical Infectious Diseases, showed that patients who initially received Pfizer's antifungal agent VFEND (voriconazole) were more likely to survive than patients who initially received amphotericin B deoxycholate. The analysis also showed that patients who started on VFEND were less likely to need salvage therapy than those on amphotericin B. Salvage therapy is treatment given after the infection has not responded to the initial treatment or if the patient cannot tolerate the initial medicine.

Invasive aspergillosis is a severe pulmonary infection that can occur in patients with weakened immune systems. The fatality rate for invasive aspergillosis is estimated to be 58 percent, but approaches 90 to 100 percent in patients whose infection has spread beyond the primary site.

"These high mortality rates for invasive aspergillosis underscore the importance of initial treatment for this often fatal infection," said Dr. Thomas F. Patterson, lead author of the analysis and professor of medicine at the University of Texas Health Science Center at San Antonio. "Our analysis demonstrates that voriconazole's efficacy and tolerability make it an important choice for first-line therapy."

About The Study

The Global Comparative Aspergillosis Study (GCAS) led to VFEND's 2002 approval for the first-line treatment of invasive aspergillosis and was the basis for this newly published analysis. In that study, 144 patients with confirmed or probable invasive aspergillosis were started on VFEND and 133 were started on amphotericin B. If the disease progressed or the patient was unable to tolerate initial therapy, treatment could be chang
'"/>

Contact: Jeanne Traflet
jeanne.traflet@pfizer.com
212-733-0127
Edelman Public Relations
25-Oct-2005


Page: 1 2 3

Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Reanalysis of controversial meta-analysis says writing off rosiglitazone may be premature
3. Panel offers expert analysis on causes, prevention of stent thrombosis
4. Circumcision for prevention of HIV: new analysis demonstrates cost-effectiveness
5. Cost-benefit analysis: Combo treatment costs more, saves money later
6. Oral contraceptives increase risk for breast cancer in some women, meta-analysis finds
7. Beta-agonist inhalers more than double death rate in COPD patients, analysis shows
8. New analysis showed UC patients in clinical remission had higher rates of employment
9. Nanotechnology expert analysis: Huge impacts from tiny tech
10. WHI updated analysis: No increased risk of breast cancer with estrogen-alone
11. Awareness, analysis of tobacco advertising may go long way (baby) to prevent teen smoking

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
Breaking Medicine Technology:
Cached News: